| BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly |
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CEO, what is means for the company's trajectory, and more. |
youtube.com |
2025-05-16 16:29:35 |
Czytaj oryginał (ang.) |
| Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It |
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-05-16 14:05:20 |
Czytaj oryginał (ang.) |
| Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript |
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America. |
seekingalpha.com |
2025-05-15 18:51:58 |
Czytaj oryginał (ang.) |
| 2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed |
President Donald Trump's first 100 days in office occurred between Monday, Jan. 20, and Tuesday, April 29. During this period, the S&P 500 (^GSPC 0.10%) and Nasdaq Composite (^IXIC 0.72%) dropped by 7% and 11%, respectively. |
fool.com |
2025-05-15 08:55:00 |
Czytaj oryginał (ang.) |
| Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock? |
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects. |
zacks.com |
2025-05-14 13:55:47 |
Czytaj oryginał (ang.) |
| PFE vs. LLY: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-05-13 16:45:41 |
Czytaj oryginał (ang.) |
| Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order. |
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say. |
barrons.com |
2025-05-13 15:18:00 |
Czytaj oryginał (ang.) |
| Why Lilly (LLY) International Revenue Trends Deserve Your Attention |
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock. |
zacks.com |
2025-05-13 14:21:54 |
Czytaj oryginał (ang.) |
| Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared |
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices. |
zacks.com |
2025-05-13 12:40:53 |
Czytaj oryginał (ang.) |
| NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs |
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector. |
fxempire.com |
2025-05-13 12:40:10 |
Czytaj oryginał (ang.) |
| 50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy |
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading. |
seekingalpha.com |
2025-05-12 22:25:11 |
Czytaj oryginał (ang.) |
| Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical |
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. |
youtube.com |
2025-05-12 17:21:43 |
Czytaj oryginał (ang.) |
| Drugmakers are spared worst-case drug pricing scenario for now |
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan. |
wsj.com |
2025-05-12 17:14:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial |
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight. |
proactiveinvestors.com |
2025-05-12 14:46:51 |
Czytaj oryginał (ang.) |
| Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs |
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug. |
zacks.com |
2025-05-12 14:41:06 |
Czytaj oryginał (ang.) |
| Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy |
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs. |
wsj.com |
2025-05-12 13:12:00 |
Czytaj oryginał (ang.) |
| Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025) |
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. |
247wallst.com |
2025-05-12 12:25:54 |
Czytaj oryginał (ang.) |
| Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices |
Trump said he would lower the cost of medicines for Americans by between 30% and 80%. |
barrons.com |
2025-05-12 11:10:00 |
Czytaj oryginał (ang.) |
| Eli Lilly investing $27B more in US manufacturing |
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion. |
foxbusiness.com |
2025-02-27 13:41:35 |
Czytaj oryginał (ang.) |
| Eli Lilly plans to invest $27B to build four new US plants as tariffs loom |
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers. |
nypost.com |
2025-02-26 18:06:01 |
Czytaj oryginał (ang.) |
| Committee Stocks on the Move: Lowe's, TJX Companies, Eli Lilly and the XLV |
The Investment Committee discuss some of their stocks that are moving today. |
youtube.com |
2025-02-26 16:00:39 |
Czytaj oryginał (ang.) |
| Eli Lilly Latest US Company to Commit to Domestic Investments |
Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs. |
investopedia.com |
2025-02-26 15:56:08 |
Czytaj oryginał (ang.) |
| Eli Lilly announces $27B investment in US drug manufacturing |
Eli Lilly and Co (NYSE:LLY) plans to invest at least $27 billion in four new US manufacturing facilities, the company announced during an event in Washington DC. Three of the facilities will focus on producing active pharmaceutical ingredients (APIs) for drugs like Zepbound and Mounjaro, while the fourth will expand the company's capacity for future injectable medications. |
proactiveinvestors.com |
2025-02-26 14:36:40 |
Czytaj oryginał (ang.) |
| Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites |
Eli Lilly & Co.'s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs. |
marketwatch.com |
2025-02-26 13:53:00 |
Czytaj oryginał (ang.) |
| Eli Lilly CEO on $27 billion in new U.S. manufacturing investments |
Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs. |
youtube.com |
2025-02-26 13:35:28 |
Czytaj oryginał (ang.) |
| Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion |
CNBC's Angelica Peebles and Eli Lilly CEO David Ricks, join 'Squawk on the Street' to discuss the company's U.S. manufacturing sites expansion, tariffs and domestic jobs. |
youtube.com |
2025-02-26 13:06:42 |
Czytaj oryginał (ang.) |
| Lilly plans to invest $27 billion in new US plants as Trump threatens pharmaceutical tariffs |
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the threat of drug import duties from the Trump administration. |
reuters.com |
2025-02-26 11:38:11 |
Czytaj oryginał (ang.) |
| Novo Nordisk should withstand competition from new Eli Lilly diabetes drug, says Wall Street bank |
JP Morgan is optimistic about Novo Nordisk (NYSE:NVO) despite competition from Eli Lilly's new drug, orforglipron. Its analysts reckon Novo will hold its ground if Lilly's upcoming trial results match Novo's existing treatments. |
proactiveinvestors.co.uk |
2025-02-26 11:32:56 |
Czytaj oryginał (ang.) |
| Eli Lilly plans at least $27 billion in new U.S. manufacturing investments |
Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs. The move comes as companies work to build goodwill with President Donald Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains. |
cnbc.com |
2025-02-26 11:30:01 |
Czytaj oryginał (ang.) |
| Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion |
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history INDIANAPOLIS , Feb. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. |
prnewswire.com |
2025-02-26 11:30:00 |
Czytaj oryginał (ang.) |
| Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients |
Eli Lilly (LLY) on Tuesday lowered the price of its weight-loss drug Zepbound for some patients paying out of pocket and introduced two new available vial doses. |
investopedia.com |
2025-02-25 15:31:36 |
Czytaj oryginał (ang.) |
| Why Eli Lilly Stock Popped Today |
Eli Lilly (LLY 2.10%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. |
fool.com |
2025-02-25 14:35:00 |
Czytaj oryginał (ang.) |
| Eli Lilly introduces new doses of weight loss drug Zepbound at discounted prices |
Eli Lilly and Co (NYSE:LLY) has announced a reduction in the price of its weight-loss medication Zepbound for patients who pay for the drug out of pocket. The company is now offering higher-dose 5mg vials of Zepbound at a discounted rate of $499 per month, a $150 decrease from the previous price of $649 for the auto-injector pen versions. |
proactiveinvestors.com |
2025-02-25 14:06:30 |
Czytaj oryginał (ang.) |
| Eli Lilly: Load Up Before It Leaves You Behind |
Eli Lilly investors have been "quietly" loading up, as the stock outperformed the S&P 500. Lilly has been making gains against Novo Nordisk, and the advance may not be over. Policy risks and pricing changes could be risks to consider later, but the stock is still assessed to be undervalued when we consider LLY's PEG ratio. |
seekingalpha.com |
2025-02-25 11:00:00 |
Czytaj oryginał (ang.) |
| Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients |
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease. |
marketwatch.com |
2025-02-25 09:53:00 |
Czytaj oryginał (ang.) |
| Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month |
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses. |
barrons.com |
2025-02-25 09:49:00 |
Czytaj oryginał (ang.) |
| Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen |
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine. |
reuters.com |
2025-02-25 08:48:33 |
Czytaj oryginał (ang.) |
| Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access |
Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the blockbuster injection, such as those with Medicare. The company is offering those vials through its direct-to-consumer website, LillyDirect, which started offering lower doses of the drug in vials in August. |
cnbc.com |
2025-02-25 08:45:01 |
Czytaj oryginał (ang.) |
| 7 Investments To Avoid In 2024: The Reckoning |
As is usual at the start of a new year, many Seeking Alpha contributors will have their lists of where to put your money during the next year. But not losing money with your investments is almost as important as making money. At the beginning of this year, I wrote an article about which stocks to avoid in 2024. |
seekingalpha.com |
2025-01-05 06:33:59 |
Czytaj oryginał (ang.) |
| Prediction: These 3 Healthcare Stocks Will Soar in 2025 |
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good. |
fool.com |
2025-01-04 08:48:00 |
Czytaj oryginał (ang.) |
| Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz |
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year |
youtube.com |
2025-01-03 14:06:01 |
Czytaj oryginał (ang.) |
| Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know |
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-01-03 12:01:18 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer |
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog. |
zacks.com |
2025-01-03 05:46:16 |
Czytaj oryginał (ang.) |
| Lilly asks to join lawsuit over compounded versions of its weight-loss drugs |
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply. |
reuters.com |
2025-01-02 16:18:04 |
Czytaj oryginał (ang.) |
| 5 Large Drug Stocks to Keep An Eye On in the New Year |
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio. |
zacks.com |
2025-01-02 12:02:09 |
Czytaj oryginał (ang.) |
| Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025 |
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers, employers and government health programs who cover it in 2025. |
forbes.com |
2025-01-01 15:00:32 |
Czytaj oryginał (ang.) |
| Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There's a Clear Winner. |
It hasn't been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them. |
barrons.com |
2024-12-31 11:52:00 |
Czytaj oryginał (ang.) |
| Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better |
With only one trading day left in 2024, the S&P 500 Index is up approximately 23%. However, as investors look back on the year, they'll see a textbook example of why the stock market is a poor proxy for the economy, which has delivered unclear and, in some cases, conflicting data points. |
marketbeat.com |
2024-12-31 11:01:51 |
Czytaj oryginał (ang.) |
| Dividends Done Right: 3 Stock Picks To Build Wealth The Smart Way |
The market is obsessed with risky options, but disciplined investors know slow & steady wins. I highlight the power of dividend growth investing for long-term wealth creation, offering a less volatile. I explore three companies poised to benefit from major trends: one from the options craze itself, another from a booming healthcare sector, and a third from unique real estate opportunities. These picks offer attractive valuations, consistent dividend growth, and a high potential for long-term returns. They prove you don't need excessive risk for great results—just a focus on solid fundamentals. |
seekingalpha.com |
2024-12-31 09:30:00 |
Czytaj oryginał (ang.) |
| Why Eli Lilly (LLY) Dipped More Than Broader Market Today |
Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close. |
zacks.com |
2024-12-30 20:50:25 |
Czytaj oryginał (ang.) |
| My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks |
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I discuss two scenarios of hypothetical investors who start their journey in 2025. I detail the significant impact a long-term commitment – even without additional investments – can make. |
seekingalpha.com |
2024-12-30 12:00:38 |
Czytaj oryginał (ang.) |
| Will This Major Pharmaceutical Stock Announce a Stock Split in 2025? |
Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors. |
fool.com |
2024-12-30 06:30:00 |
Czytaj oryginał (ang.) |
| Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders |
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors. |
fool.com |
2024-12-29 07:39:00 |
Czytaj oryginał (ang.) |
| Is Eli Lilly Stock a Buy? |
While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself "Ozempic Santa," he wasn't taking Ozempic. |
fool.com |
2024-12-29 06:35:00 |
Czytaj oryginał (ang.) |
| 2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades |
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory. |
fool.com |
2024-12-28 08:05:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 |
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near-term projections irrelevant. 24/7 Wall Street aims to present some farther-looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. Novo Nordisk News and Updates 12/20/2024 Novo Nordisk’s stock price plummeted by as much as 24% today. This was due to disappointing late-stage trial results for its experimental weight-loss drug, CagriSema. 12/18/2024 Novo Nordisk has partnered with Photys Therapeutics to develop a novel therapeutic targeting an undisclosed cardiometabolic disease. The partnership leverages Photy’s proprietary PHICS technology, which holds promise for addressing unmet medical needs in the cardiometabolic field. 12/16/2024 Novo Nordisk announced a large investment of $1.2 billion to build a new production facility in Denmark. The new state-of-the-art facility, located in Odense, will focus on manufacturing medications for rare diseases. 12/13/2024 A recent study published on medRxiv, though not yet peer-reviewed, suggests a possible link between Novo Nordisk’s weight-loss drug Ozempic and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). This finding also aligns with research from Harvard University earlier this year. 12/12/2024 Novo Nordisk has received European approval for a new indication of its drug, Ozempic. The European Medicines Agency (EMA) has authorized a label expansion to include the treatment of chronic kidney disease in adults with type 2 diabetes. This decision follows a study demonstrating a 20% reduction in the risk of kidney-related death for patients taking Ozempic. 12/11/2024 Novo Nordisk is partnering with the Sher-i-Kashmir Institute of Medical Sciences (SKIMS) to drive clinical research in India. The collaboration will focus on addressing critical medical needs in nephrology, rare diseases, cardiology, and obesity. 12/9/2024 Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However, the deal still needs to be cleared by the U.S. Federal Trade Commission before it can be finalized. 12/6/2024 Novo Nordisk announced a major price reduction for two of its insulin products. Starting in January 2026, the list price of Fiasp will drop by 75%, while Tresiba will see a 72.2% reduction. Novo Nordisk will also discontinue unbranded versions of Tresiba by the end of 2025. 12/5/2024 Novo Nordisk announced a large investment of DKK 2.9 billion ($411 million) to construct a new quality control laboratory in Hillerød, Denmark. The new 53,000-square-meter facility is expected to be operational by 2027 and will be Novo Nordisk’s largest quality control investment to date. 12/3/2024 Novo Nordisk’s India team wants to launch the weight-loss drug Wegovy sooner than planned. They’re concerned about falling behind the company’s rival, Eli Lilly, whose similar drug Mounjaro is expected to launch next year. 11/27/2024 Health Canada has granted approval for Novo Nordisk’s weight-loss drug, Wegovy. Wegovy now becomes the first treatment in Canada to address both obesity and the risk of heart-related issues in adults with pre-existing cardiovascular disease. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 60.32% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be 42.15% above today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals require drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 Get Ready To Retire (Sponsored) Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. Here’s how it works: 1. Answer SmartAsset advisor match quiz 2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles. 3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future Get started right here. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St.. |
https://247wallst.com |
2024-12-27 06:30:39 |
Czytaj oryginał (ang.) |
| Better Buy: Eli Lilly vs. Novo Nordisk. |
It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines as each of these businesses played an integral role in the development of vaccines used to treat COVID-19. |
fool.com |
2024-12-26 12:15:00 |
Czytaj oryginał (ang.) |
| Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 |
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side-effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone. Headwinds While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones being: A 2017 $59 million fine from the DOJ due to lack of FDA disclosures concerning cancer risks from diabetes drug Victoza; Membership suspension from the UK’s Association of British Pharmacy Industry over ethics violations tantamount to bribing of health professionals; 235 active Ozempic related product liability lawsuits as of August, 2024; A 2024 investigation led by the US Senate confirmed predatory pricing of Ozempic by almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over the next 1, 5, to 10 years. While most Wall Street analysts will calculate 12-month forward projections, it’s clear that nobody has a consistent crystal ball, and plenty of unforeseen circumstances can render even near-term projections irrelevant. 24/7 Wall Street aims to present some farther-looking insights based on Novo Nordisk’s own numbers, along with business and market development information that may be of help to our readers’ own research. Key Points In This Article Novo Nordisk’s R&D is heavily invested in improved obesity treatments Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has Amycretin in FDA phase-1 and CagriSegma in phase-2 trials, which both show greater efficacy potential than Wegovy and Ozempic. Although the number of Ozempic-related lawsuits are piling up, Novo Nordisk’s stance is that the complaints are unwarranted, and will either be dismissed or settled. Novo Nordisk’s past acquisitions for both greater production capacity and logistical flexibility will reap benefits through geopolitical risk mitigation and broader product menu options. Entering untapped markets, such as China, will be key to Novo Nordisk’s future growth. If you’re looking for some stocks with huge potential, make sure to grab a free copy of our brand-new “The Next NVIDIA” report. It features a software stock we’re confident has 10X potential. Novo Nordisk News and Updates 12/20/2024 Novo Nordisk’s stock price plummeted by as much as 24% today. This was due to disappointing late-stage trial results for its experimental weight-loss drug, CagriSema. 12/18/2024 Novo Nordisk has partnered with Photys Therapeutics to develop a novel therapeutic targeting an undisclosed cardiometabolic disease. The partnership leverages Photy’s proprietary PHICS technology, which holds promise for addressing unmet medical needs in the cardiometabolic field. 12/16/2024 Novo Nordisk announced a large investment of $1.2 billion to build a new production facility in Denmark. The new state-of-the-art facility, located in Odense, will focus on manufacturing medications for rare diseases. 12/13/2024 A recent study published on medRxiv, though not yet peer-reviewed, suggests a possible link between Novo Nordisk’s weight-loss drug Ozempic and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). This finding also aligns with research from Harvard University earlier this year. 12/12/2024 Novo Nordisk has received European approval for a new indication of its drug, Ozempic. The European Medicines Agency (EMA) has authorized a label expansion to include the treatment of chronic kidney disease in adults with type 2 diabetes. This decision follows a study demonstrating a 20% reduction in the risk of kidney-related death for patients taking Ozempic. 12/11/2024 Novo Nordisk is partnering with the Sher-i-Kashmir Institute of Medical Sciences (SKIMS) to drive clinical research in India. The collaboration will focus on addressing critical medical needs in nephrology, rare diseases, cardiology, and obesity. 12/9/2024 Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However, the deal still needs to be cleared by the U.S. Federal Trade Commission before it can be finalized. 12/6/2024 Novo Nordisk announced a major price reduction for two of its insulin products. Starting in January 2026, the list price of Fiasp will drop by 75%, while Tresiba will see a 72.2% reduction. Novo Nordisk will also discontinue unbranded versions of Tresiba by the end of 2025. 12/5/2024 Novo Nordisk announced a large investment of DKK 2.9 billion ($411 million) to construct a new quality control laboratory in Hillerød, Denmark. The new 53,000-square-meter facility is expected to be operational by 2027 and will be Novo Nordisk’s largest quality control investment to date. 12/3/2024 Novo Nordisk’s India team wants to launch the weight-loss drug Wegovy sooner than planned. They’re concerned about falling behind the company’s rival, Eli Lilly, whose similar drug Mounjaro is expected to launch next year. 11/27/2024 Health Canada has granted approval for Novo Nordisk’s weight-loss drug, Wegovy. Wegovy now becomes the first treatment in Canada to address both obesity and the risk of heart-related issues in adults with pre-existing cardiovascular disease. 5-10 Year Review Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment, and HGH, among others. Novo Nordisk has spared no expense in expanding its pharmaceutical reach and scope. In addition to adding new factories to ramp up production to meet demand for Ozempic and Wegovy, the company’s expansion towards treating other afflictions saw billions spent in acquisitions. The past decade has seen the following events: In 2015, Novo Nordisk announced a $400 million collaboration with Sanofi subsidiary Ablynx, to use its nanobody technology to develop a new drug. After an unsuccessful bid to acquire Ablynx in 2018, Novo Nordisk bought diabetes drug company Ziylo. 2020 saw Novo Nordisk buying Corvidia Therapeutics from AstraZeneca for its heart disease treatments. Novo Nordisk announced it would acquire Emisphere Technologies for $1.35 billion in December 2020, adding another diabetes pill to its catalog. In November 2021, Novo Nordisk acquired Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion. Intending to expand its sickle cell disease and rare blood disorders portfolio, 2022 saw Novo Nordisk buying Forma Therapeutics for $1.1 billion. Flush with Ozempic and Wegovy cash, Novo Nordisk bought Inversago Pharma for $1 billion, Embark Biotech for up to $500 million, ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion during 2023. To address expanding Ozempic and Wegovy demand, Novo Nordisk’s parent, Novo Holdings, bought NJ-based Catalent, a global provider of drug delivery systems, gene therapies, manufacturing, biologics, and other operations, in 2024. 2024 also saw the acquisitions of Cardior Pharmaceuticals for its cardiovascular treatment portfolio, and Austria’s Single use Support, a fluid management company. Fiscal Year (DEC) Price Revenues Net Income DKK (=US$0.15) DKK (=US$0.15) 2015 $29.04 107.927B/$16.19B 34.860B/$5.23B 2016 $17.93 111.780B/$16.76B 37.925B/$5.69B 2017 $26.83 111.696B/$16.75B 38.130B/$5.72B 2018 $23.03 111.831B/$16.77B 38.628B/$5.79B 2019 $28.94 122.021B/$18.30B 38.951B/$5.84B 2020 $34.92 126.946B/$19.04B 42.138B/$6.32B 2021 $56.00 140.800B/$21.12B 47.757B/$7.16B 2022 $67.67 176.954B/$26.54B 55.525B/$8.33B 2023 $103.45 232.261B/$34.84B 83.683B/$12.55B 2024 LTM (as of June) $142.74 258.003B/$38.70B 89.898B/$13.48B Key Drivers for Novo Nordisk’s Stock in the Future The obesity and weight-loss drug market is expected to his $100 billion by 2030. A more potent obesity treatment called CagriSema combines semaglutide, the active ingredient in Ozempic, with amylin and calcitonin receptor agonists. Amylin helps regulate blood sugar levels, similar to GLP-1, while calcitonin controls calcium levels in the blood. Results for two late-stage FDA trials of the drug are expected by the end of 2024. Wegovy’s June 2024 approval for sales in China opens the door to a new market, which has hundreds of million prospective new customers from China’s burgeoning middle and upper class. New experimental obesity drug Amycretin, a single molecule that operates as a GLP-1 receptor agonist that reduces one’s appetite, is in phase-1 FDA trials. The new pill achieved a 13.1% average weight loss after 12 weeks, more than doubling the efficacy of Wegovy for the same time span. With the obesity drug market expected to reach $100 billion by 2030, genetic-based treatments currently in the R&D stage could become the next pharma golden ring. While some legal experts believe that the number of Ozempic lawsuits over gastroparesis and other afflictions, such as pancreatitis, kidney, and gallbladder issues, can reach as high as 20,000, Novo Nordisk is apparently confident it can reach a settlement that will allow it to continue its growth trajectory without impediment. Stock Price Prediction for 2025 Out of 11 Wall Street analysts, their consensus recommendation is “outperform/hold”, based on 5 buy, 2 outperform, 2 hold, and 2 sell. Their consensus 12-month target price for Novo Nordisk is $140.07, which is a 57.90% gain over today’s stock price. The 24/7 Wall Street 12-month projected target is a more conservative $124.20. This would be 40.01% above today’s price. Novo Nordisk’s Next 5 Years’ Outlook Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals require drugs that meet the following criteria: Sufficient efficacy to fulfill the medical needs of a large population of patients; Tolerable enough for prolonged patient treatment to obtain a significant and consistent therapeutic effect; Flexible enough to be prescribed to patients without an abundance of diagnostic testing or monitoring; Formulaically efficient enough to manufacture and distribute at scale. With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially larger market than the entirety of its European share. China’s middle and wealthy classes have multiplied exponentially as China’s GDP has grown. Obesity, heart diseases, and other ailments common in the West have escalated in China as diets and lifestyles adapted to mimic Western tastes and trends. Our price target for 2026 is $136.62. The new obesity drug CagriSema is presently near completion of FDA phase-2 trials. Assuming there are no negative results to bar initiating clinical phase-3 trials, these would presumably occur throughout 2025 and 2026. Therefore, CagriSema is likely to be cleared for public dissemination and ready for market by 2027. Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction in 32 weeks, over Wegovy. Our price target for 2027 is $153.01. Although Novo Nordisk’s pipeline of new drugs under FDA review targets obesity, its revamped product menu has expanded via acquisitions. Revenues from its HGH, estrogen replacement, and wound treatment products, as well as other diabetes variants, should all contribute to the bottom line with full production, marketing, and sales integration by 2028. We predict a price of $165.26. Obesity pill Amecrytin, which acts as an appetite suppressant without the effects of amphetamines, is presently in FDA phase-1 trials, but should be cleared for market and ready for distribution in 2029. Its weight-loss efficacy doubles that of Wegovy in shorter 3-month periods, and its pill configuration convenience should make it a hit prescription for doctors. Our price target is $186.74. Novo Nordisk Stock in 2030 Ozempic is an injection administered drug. R&D for a genetic based obesity drug is currently in the works by Novo Nordisk, Eli Lilly, and several other rivals. With the obesity treatment market expected to hit $100 billion in 2030, even the announcement of a genetic-based drug ready to start FDA trials would generate significant buzz. With Novo Nordisk the current market leader, such an announcement in 2030 is not a stretch. Our target price is $192.34. Cumulatively, 24/7 Wall Street anticipates Novo Nordisk to appreciate 79% over the next 5 years. Year EPS P/E multiple Price 2025 $4.97 25 $124.20 2026 $5.46 25 $136.62 2027 $6.12 25 $153.01 2028 $6.61 25 $165.26 2029 $7.47 25 $186.74 2030 $7.69 25 $192.34 Want to Retire Early? Start Here (Sponsor) Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free. Click here to match with up to 3 financial pros who would be excited to help you make financial decisions. The post Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St.. |
https://247wallst.com |
2024-12-26 06:25:03 |
Czytaj oryginał (ang.) |